...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Case Reports in Cardiology >Respiratory Syncytial Virus Pneumonia Treated with Lower-Dose Palivizumab in a Heart Transplant Recipient
【24h】

Respiratory Syncytial Virus Pneumonia Treated with Lower-Dose Palivizumab in a Heart Transplant Recipient

机译：在心脏移植接受者中用小剂量帕利珠单抗治疗呼吸道合胞病毒性肺炎

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Respiratory syncytial virus (RSV) is an important community-acquired pathogen that can cause significant morbidity and mortality in patients who have compromised pulmonary function, are elderly, or are immunosuppressed. This paper describes a 70-year-old man with a remote history of heart transplantation who presented with signs and symptoms of pneumonia. Chest computed tomography (CT) imaging demonstrated new patchy ground glass infiltrates throughout the upper and lower lobes of the left lung, and the RSV direct fluorescence antibody (DFA) was positive. The patient received aerosolized ribavirin, one dose of intravenous immunoglobulin, and one dose of palivizumab. After two months of followup, the patient had improved infiltrates on chest CT, improved pulmonary function testing, and no evidence of graft rejection or dysfunction. There are few data on RSV infections in heart transplant patients, but this case highlights the importance of considering this potentially serious infection and introduces a novel method of treatment.
机译：呼吸道合胞病毒（RSV）是一种重要的社区获得性病原体，可在肺功能受损，年老或免疫抑制的患者中引起明显的发病率和死亡率。本文介绍了一名70岁的心脏病患者，他的心脏移植史遥远，他出现了肺炎的体征和症状。胸部计算机断层扫描（CT）成像显示新的斑块状玻璃碎片浸润遍及左肺的上，下叶，并且RSV直接荧光抗体（DFA）呈阳性。该患者接受了雾化的利巴韦林，一剂静脉注射免疫球蛋白和一剂帕利珠单抗。经过两个月的随访，患者的胸部CT浸润情况得到改善，肺功能检查得到改善，并且没有移植物排斥或功能障碍的迹象。关于心脏移植患者中RSV感染的数据很少，但是这种情况突出了考虑这种潜在严重感染的重要性，并介绍了一种新颖的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号